Territorial Availability: Available through Bertin Technologies only in France
- Correlated keywords
- SQSTM-1 Phox-1 Bem-1p PB-1 p-62 LC-3 Keap-1 TRAF-6 ERK-1 RIP-1 mTORC-1 NRF-2 SQSTM-1
- Product Overview:
p62, also known as sequestosome-1 (SQSTM1), is a 62 kDa protein that acts as a signaling hub and autophagy substrate and adaptor.{39547,39548} It is a multi-domain protein that includes a Phox1 and Bem1p (PB1) domain, a zinc finger, a tumor necrosis factor receptor-associated factor 6 (TRAF6) binding domain, a ubiquitin-associated (UBA) domain, LC3- and Keap1-interacting regions, as well as two nuclear localization and one nuclear export sequence. p62/SQSTM1 is constitutively expressed and is primarily localized in the cytoplasm, however, it is also expressed in the nucleus, autophagosomes, lysosomes, and inclusion bodies containing polyubiquitinated protein aggregates. It is overexpressed in a variety of human cancer cells as well as in the chronic liver diseases alcoholic and non-alcoholic steatohepatitis (NASH). p62/SQSTM1 binds to ERK1, RIP1, TRAF6, Raptor, PKC, LC3, and Keap1 to activate mammalian target of rapamycin complex 1 (mTORC1), NF-?B, and nuclear factor erythroid 2-related factor 2 (NRF2) signaling in response to oxidative and endoplasmic reticulum (ER) stress. It functions as a cargo receptor in selective autophagy to shuttle aggregated and damaged proteins and organelles to autophagosomes for clearance. Mutations in the UBA domain of the SQSTM1 gene are associated with Paget’s diseases. Cayman’s p62/SQSTM1 Polyclonal Antibody can be used for WB and ELISA applications. The antibody recognizes p62/SQSTM1 at ~60 kDa from human samples.
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.